ALVO

NASDAQ · Biotechnology

Alvotech Sa

Small-Cap Stocks Penny Stocks Biotech Stocks Healthcare Stocks

$3.26

+0.13 (+4.15%)

As of Mar 25, 1:46 PM ET ·

Financial Highlights (FY 2026)

Revenue

615.09M

Net Income

-289,876,443

Gross Margin

62.3%

Profit Margin

-47.1%

Rev Growth

+131.4%

D/E Ratio

—

Revenue & Net Income

Margin Trends

	FY 2026	FY 2025	FY 2024	FY 2023
Gross Margin	62.3%	56.3%	56.3%	56.3%
Operating Margin	0.0%	24.2%	29.6%	24.9%
Profit Margin	-47.1%	19.5%	19.5%	23.6%

Income Statement

	FY 2026	FY 2025	FY 2024	FY 2023
Revenue	615.09M	146.14M	133.98M	123.74M
Gross Profit	383.39M	82.27M	75.43M	69.66M
Operating Income	307.5K	35.36M	39.62M	30.84M
Net Income	-289,876,443	28.46M	26.13M	29.17M
Gross Margin	62.3%	56.3%	56.3%	56.3%
Operating Margin	0.0%	24.2%	29.6%	24.9%
Profit Margin	-47.1%	19.5%	19.5%	23.6%
Rev Growth	+131.4%	+3.3%	+20.0%	+10.8%

Balance Sheet

	FY 2026	FY 2025	FY 2024	FY 2023
Total Debt	—	380.05M	315.40M	394.86M
Total Equity	—	792.19M	787.29M	748.59M
D/E Ratio	—	0.48	0.40	0.53

Cash Flow

	FY 2026	FY 2025	FY 2024	FY 2023
EBITDA	11.59M	50.85M	43.53M	37.02M
Free Cash Flow	—	28.40M	33.36M	27.22M